Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;16(4):1095-1103.
doi: 10.1055/a-2595-4849. Epub 2025 Apr 28.

A Rash Decision: Implementing an EHR-Integrated Penicillin Allergy Delabeling Protocol without Adequate Clinician Support

Affiliations

A Rash Decision: Implementing an EHR-Integrated Penicillin Allergy Delabeling Protocol without Adequate Clinician Support

Alexander S Plattner et al. Appl Clin Inform. 2025 Aug.

Abstract

Approximately 10% of patients have a documented penicillin "allergy"; however, up to 95% have subsequent negative testing. These patients may receive suboptimal antibiotics, leading to longer hospitalizations and higher costs, rates of resistant and nosocomial infections, and all-cause mortality. To mitigate these risks in children, we implemented an inpatient penicillin allergy delabeling protocol and integrated it into the electronic health record (EHR) through a mixed methods approach of clinical decision support (CDS).We describe our protocol implementation across three sequential phases: "Pilot," "Active Antimicrobial Stewardship Program (ASP)," and "Mixed CDS." We highlight several potential pitfalls that may have contributed to poor clinician adoption.Patients were risk-stratified as nonallergic, low-risk, or high-risk based on history. Process measures included: evaluation rate, oral challenge rate for low-risk, and allergy referral rate for high- or low-risk when oral challenge was deferred. The primary outcome measure was the penicillin allergy delabeling rate among low-risk or nonallergic. Balancing measures included the rate of epinephrine or antihistamine administrations.The pilot and ASP phases used clinician education and an order set, but were mostly manual processes. The mixed CDS phase introduced interruptive alerts, dynamic text in note templates, and patient list columns to guide clinicians, but little education was provided. The mixed CDS phase had the lowest evaluation rate compared with the pilot and active ASP phases (6.4 vs. 25 vs. 15%). However, when the evaluation was performed, the mixed CDS phase had the highest oral challenge rate (33 vs. 26 vs. 13%) and delabeling rate (43 vs. 33 vs. 27%). No adverse events occurred.CDS tools improve clinician decision-making and optimize patient care. However, relying on CDS for complex clinical evaluations can lead to failure when clinicians cannot find the tool or appreciate its importance. Person-to-person communication can be vital in establishing a process and educating intended users for successful CDS implementation.

PubMed Disclaimer

Conflict of interest statement

E.E.F. has received funding from AbbVie Inc. for a study related to nonpenicillin antibiotic use in children but is not directly related to this study.

References

    1. Shenoy E S, Macy E, Rowe T, Blumenthal K G. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(02):188–199. - PubMed
    1. Sacco K A, Bates A, Brigham T J, Imam J S, Burton M C. Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis. Allergy. 2017;72(09):1288–1296. - PubMed
    1. DesBiens M, Scalia P, Ravikumar S et al. A closer look at penicillin allergy history: systematic review and meta-analysis of tolerance to drug challenge. Am J Med. 2020;133(04):452–4.62E6. - PubMed
    1. Caubet J C, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann P A. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol. 2011;127(01):218–222. - PMC - PubMed
    1. Blumenthal K G, Peter J G, Trubiano J A, Phillips E J.Antibiotic allergy Lancet 2019393(10167):183–198. - PMC - PubMed

MeSH terms